ライフサイエンスコーパス: immunosuppressant

1 y, pancreatitis, systemic steroids, or other immunosuppressants).

2 as an increase in the dose of steroid and/or immunosuppressant.

3 in (IL)-2 receptor antibody as a maintenance immunosuppressant.

4 -like antitumor agents; and a rapamycin-like immunosuppressant.

5 s of corticosteroids and maintenance with an immunosuppressant.

6 rapy only, consisting of corticosteroids and immunosuppressants.

7 oids, combined or not with other traditional immunosuppressants.

8 ally leading to resistance to CD28-targeting immunosuppressants.

9 izumab treatment, and with prior exposure to immunosuppressants.

10 nflammatory bowel disease (IBD) treated with immunosuppressants.

11 cific T cell levels might optimize dosing of immunosuppressants.

12 or-specific tolerance, minimizing the use of immunosuppressants.

13 of the patients received corticosteroids or immunosuppressants.

14 nse to conventional therapy with steroids or immunosuppressants.

15 plants from 1984 to 2008 treated with modern immunosuppressants.

16 rrent treatment with oral corticosteroids or immunosuppressants.

17 tivation and proliferation and are effective immunosuppressants.

18 y mice (Mus sp.) without the aid of powerful immunosuppressants.

19 aking into account the mechanistic impact of immunosuppressants.

20 s and related mTOR inhibitors are transplant immunosuppressants.

21 graft-versus-host disease (GvHD) or received immunosuppressants.

22 ds the therapeutic utility of these drugs as immunosuppressants.

23 itive patients who have not previously taken immunosuppressants.

24 trolling for important confounders including immunosuppressants.

25 roids and, for more severe disease, systemic immunosuppressants.

26 e 5-aminosalicylic acid drugs, steroids, and immunosuppressants.

27 recipients due to the use of lower doses of immunosuppressants.

28 13 on hemodynamic and fluid management, 7 on immunosuppressants, 12 on preconditioning, 34 on preserv

29 thers except people with renal failure or on immunosuppressants (2.1%, 95%CI -7.2 to 11.3).

30 rganizing protein Drebrin as a target of the immunosuppressant 3,5-bistrifluoromethyl pyrazole, which

31 with HIV; 2) with renal failure or receiving immunosuppressants; 3) using drugs or with hepatitis; 4)

32 ore commonly treated with rituximab or other immunosuppressants (63%).

33 Tacrolimus, a widely used immunosuppressant, accelerates onset of diabetes after o

34 d P2Y12, and at P2X4 and P2X7 receptors), an immunosuppressant (acting at P2Y11), and a growth-promot

35 further demonstrating the specificity of the immunosuppressant activity of CP.

36 ioned hereafter, among the clinical factors, immunosuppressants (adjusted hazard ratio [aHR] = 0.408

37 he goal of this study was to investigate how immunosuppressants affect gene expression in a manner th

38 rol by means of conventional and/or biologic immunosuppressants after remission-induction with anti-B

39 The immunosuppressant agent mycophenolic acid (MPA) has show

40 No clear association was found with any 1 immunosuppressant agent.

41 etween antiretrovirals (ARVs) and transplant immunosuppressant agents (IS) among HIV-infected transpl

42 h corticosteroids in combination with global immunosuppressant agents and/or immunomodulatory monoclo

43 unosuppression with corticosteroids or other immunosuppressant agents such as infliximab; most irAEs

44 ce (KCa3.1) is a target for antisickling and immunosuppressant agents.

45 ng-standing kidney disease and/or neurotoxic immunosuppressant agents.

46 anti-proliferative properties, which give it immunosuppressant and anti-tumor activity.

47 topurine have been extensively prescribed as immunosuppressant and anticancer agents for several deca

48 diolipins and show that prior binding of the immunosuppressant and antifungal antibiotic cyclosporin

49 (also called fingolimod) is recognized as an immunosuppressant and has been approved by the Food and

50 In our study, we found that immunosuppressants and antibiotics were associated with

51 ety of other drugs such as antitumor agents, immunosuppressants and antifungals.

52 rotocols should allow for improved dosing of immunosuppressants and better management of posttranspla

53 BS sampling for the simultaneous analysis of immunosuppressants and creatinine can replace convention

54 hildren in Group A were treated earlier with immunosuppressants and had more frequent endoscopic asse

55 ressure monitoring, spirometry), 13%-23% for immunosuppressants and other medications, and 4% for tob

56 sing encapsulation may circumvent the use of immunosuppressants and prolong the longevity of transpla

57 ) between the groups; neither were secondary immunosuppressants and use of steroids.

58 avenous immunoglobulin, plasma exchange, and immunosuppressants) and ambulatory outcomes were compare

59 es several validated targets for anticancer, immunosuppressant, and anti-inflammatory chemotherapeuti

60 success was achieved in 74% of patients on 1 immunosuppressant, and in an additional 21% of patients

61 Marijuana smoke contains cannabinoids, immunosuppressants, and a mixture of potentially-mutagen

62 drug intolerance compared with other primary immunosuppressants, and discontinuation rates are partic

63 C virus antibodies, prior or no prior use of immunosuppressants, and duration of treatment (1 to 24 m

64 cancer treatment, as antiviral drugs and as immunosuppressants, and have also displayed antibiotic a

65 ct to anti-JC virus antibodies, prior use of immunosuppressants, and increased duration of natalizuma

66 ct to anti-JC virus antibodies, prior use of immunosuppressants, and increasing duration of natalizum

67 r more therapy lines, including splenectomy, immunosuppressants, and rituximab.

68 uenced positively or negatively by different immunosuppressants, and the impact of exhaustion on graf

69 5-aminosalicylate (5-ASA), corticosteroids, immunosuppressants, anti-tumor necrosis factor (TNF) the

70 Patients treated with immunosuppressant/anti-inflammatory thiopurines are also

71 class of red-pigmented natural products with immunosuppressant, anticancer, and antimalarial activiti

72 Topical as well as systemic immunosuppressants are administered for prophylaxis.

73 Immunosuppressants are an important cause of posttranspl

74 Immunosuppressants are associated with serious and often

75 plantation, treatment with steroids or other immunosuppressants, ARF (25.5% vs. 16.3%; P = 0.004), an

76 mmune system, whereas clobetasol is a potent immunosuppressant as well as a remyelinating agent.

77 mus and 26.2% were also receiving adjunctive immunosuppressants at the last follow-up.

78 TBI case; 13 patients were already receiving immunosuppressants at the time of screening.

79 TBI case; 13 patients were already receiving immunosuppressants at the time of screening.

80 cineurin inhibitor with sirolimus as primary immunosuppressant attenuates long-term cardiac allograft

81 Among these, the immunosuppressant azathioprine and the fluoroquinolone a

82 Upon treatment with the immunosuppressant azathioprine there was significant res

83 The immunosuppressant azathioprine, the fluoroquinolone anti

84 ls inaugurates the arrival of a new class of immunosuppressants based on costimulatory blockade, an i

85 tors have received considerable attention as immunosuppressants because they are associated with a mo

86 tive for anti-JC virus antibodies, had taken immunosuppressants before the initiation of natalizumab

87 Patients who received steroids or other immunosuppressants before transplantation had lower resp

88 study establishes that "LxVP" sequences and immunosuppressants bind to the identical site on CN.

89 ch as cyclosporine A and FK506 are effective immunosuppressants but produce severe side effects.

90 by S. aureus and moonlights as a macrophage immunosuppressant by reducing Toll-like receptor 1/2 (TL

91 Immunosuppressants can induce hepatitis B virus (HBV) re

92 himaera were more likely to be prescribed an immunosuppressant compared with all other patients (AOR,

93 Taking immunosuppressants concomitantly was prohibited.

94 = 2.4 x 10(-5)), which is consistent with an immunosuppressant contribution of IT.

95 duscin's aglycone, and bacterial cell-coated immunosuppressants could be a general strategy to combat

96 l of whom were affected by BIPA by extending immunosuppressant coverage under BIPA.

97 ransplant survival associated with extending immunosuppressant coverage was reduced to 50% of that ob

98 Thalassospiramides A and B are immunosuppressant cyclic lipopeptides first reported fro

99 Moreover, effects of the prototypic immunosuppressant cyclosporin A (CsA) were investigated.

100 ta for the complex of cyclophilin A with the immunosuppressant cyclosporin A.

101 contrast, treating activated rCD4s with the immunosuppressant cyclosporin, a calcineurin inhibitor,

102 ) best known as the cellular receptor of the immunosuppressant cyclosporine A.

103 Organ transplant recipients using the immunosuppressant cyclosporine have an increased risk fo

104 imals receiving intestinal grafts without an immunosuppressant developed antidonor IgG in 14 days and

105 d transplant recipients who receive lifelong immunosuppressant drug coverage compared with a cohort o

106 ze associations between NR1I2 polymorphisms, immunosuppressant drug exposure, and clinical outcomes i

107 Tacrolimus, a widely prescribed immunosuppressant drug for organ transplant patients, wa

108 Moreover, nasal administration of the immunosuppressant drug FTY720/fingolimod reduced ORMDL3

109 optically controlling the metabolism of the immunosuppressant drug mycophenolate mofetil.

110 in the era of generic equivalents may inform immunosuppressant drug policy.

111 The immunosuppressant drug rapamycin exerts its therapeutic

112 There were differences in the immunosuppressant drug therapy in monotherapy as well as

113 g site of the 12-kDa binding protein for the immunosuppressant drug, FK506.

114 tential to be developed as a new category of immunosuppressant drugs acting via autophagy induction o

115 pendent phosphatase that is inhibited by the immunosuppressant drugs cyclosporine and tacrolimus.

116 Medicare coverage of immunosuppressant drugs for kidney transplant recipients

117 Immunosuppressant drugs reduced and multiple sclerosis d

118 Transplant patients treated with immunosuppressant drugs such as cyclosporine A (CsA), an

119 Immunosuppressant drugs such as cyclosporine and tacroli

120 Kidney transplant recipients must take immunosuppressant drugs to prevent rejection and maintai

121 can be rapidly adopted for the detection of immunosuppressant drugs, alpha-amylase protein, or prote

122 d risk of side effects with prolonged use of immunosuppressant drugs.

123 transducing functions and susceptibility to immunosuppressant drugs.

124 -76 mg/L]; P=0.006) and a trend toward fewer immunosuppressants drugs used before biologics (P=0.054)

125 le to clearly define the role of concomitant immunosuppressants during initiation therapy with a biol

126 although combinations of glucocorticoids and immunosuppressants (e.g., cyclophosphamide, azathioprine

127 Immunosuppressants, erythropoiesis-stimulating agents in

128 n and often requires treatment with systemic immunosuppressants, extracorporeal photopheresis, or pho

129 to the tumor antigen, and treatment with the immunosuppressant FK506 (tacrolimus) decreases CSF white

130 sruption of the Hom3:Fpr1 interaction by the immunosuppressant FK506, illustrating the assay's capaci

131 PPIase) activity which is inhibitable by the immunosuppressants FK506 and rapamycin.

132 endent ser/thr phosphatase and the target of immunosuppressants, FK506 and cyclosporin A (CSA).

133 The critical role of CsA/FK506 as an immunosuppressant following transplantation surgery prov

134 hloroquine is the most frequently prescribed immunosuppressant for the syndrome.

135 A (CsA) and tacrolimus (FK506) are valuable immunosuppressants for a range of clinical settings, inc

136 ssants, antipsychotics, anticonvulsants, and immunosuppressants for transplant patients) that would l

137 ansplant patients, FK778 (an investigational immunosuppressant from the malononitrilamides class) was

138 Notably, two seemingly unrelated immunosuppressants, FTY720 and rapamycin, targeted the s

139 immunosuppressant group and 24 months in the immunosuppressant group.

140 The use of topical immunosuppressants has been anecdotally reported for the

141 ith aquaporin-4 antibodies who are receiving immunosuppressants has not been reported to date.

142 prognosis is poor but treatments, typically immunosuppressants, have improved survival, albeit with

143 ustment for confounders including the use of immunosuppressants, having NASH was independently associ

144 lmonary fibrosis by increasing levels of the immunosuppressant IL-10.

145 potentially linked to side effects of their immunosuppressants.Immunosenescence is a physiological p

146 ve in this patient population, likely due to immunosuppressants impairing test performance.

147 ve in this patient population, likely due to immunosuppressants impairing test performance.

148 Sirolimus is being used increasingly as an immunosuppressant in allogeneic hematopoietic stem cell

149 ing into question the use of rapamycin as an immunosuppressant in islet transplantation and as a seco

150 Gilenya) is a sphingosine analog used as an immunosuppressant in multiple sclerosis patients.

151 yzed the potential of sirolimus as a primary immunosuppressant in the long-term attenuation of cardia

152 S1P analogue FTY720 has been developed as an immunosuppressant in transplantation and tested as a tre

153 with systemic steroids in 28 cases (61%) and immunosuppressants in 32 cases (69.5%).

154 antigen (HLA) antibodies after withdrawal of immunosuppressants in 35 type 1 diabetic recipients of i

155 m for the off-label prescription of systemic immunosuppressants in AD, discusses the apparent dilemma

156 Still, individuals treated with immunosuppressants in ambulatory care are at increased r

157 al disease (IPD) in individuals treated with immunosuppressants in ambulatory care.

158 ndations on endpoints for clinical trials on immunosuppressants in lung transplantation.

159 nd cyclosporine, are widely used as standard immunosuppressants in organ transplantation recipients.

160 The multimorbid burden and use of systemic immunosuppressants in people with psoriasis may confer g

161 the way to study the differential effects of immunosuppressants in posttransplantation malignancy.

162 eparations are one of the most commonly used immunosuppressants in the United States.

163 esting approach for narrow therapeutic index immunosuppressants in transplant recipients have been la

164 sphatase calcineurin, an important target of immunosuppressants in transplantation biology.

165 d plasma exchange for acute attacks and with immunosuppressants (in particular, B cell-depleting agen

166 In a model of immunosuppressant-induced hyperglycemia, both TAC and SI

167 rst study to show that metformin can improve immunosuppressant-induced hyperglycemia, when administer

168 ease, and for patients failed by steroid and immunosuppressant induction therapies.

169 to selectively inactivate immune cells with immunosuppressants is a much sought-after modality for t

170 n multivariate analysis, treatment with both immunosuppressant (IS) and anti-TNF before colectomy was

171 addition, rapamycin, a clinically important immunosuppressant, is a specific and potent inhibitor of

172 sure to determine the best method to monitor immunosuppressant levels.

173 Adherence was evaluated via self-report and immunosuppressant levels.

174 Adenosine is a powerful immunosuppressant (mainly acting at A2A receptors) and a

175 RQoL, suggesting that use of non-nephrotoxic immunosuppressants may affect the patient's side effect

176 Mycophenolate mofetil is a potent immunosuppressant medication approved by the Food and Dr

177 adherers perceived that their transplant and immunosuppressant medication caused more symptoms and we

178 Nonadherence to immunosuppressant medication is a significant problem am

179 oimmune recurrence, alloimmune rejection, or immunosuppressant medication toxicity.

180 ey transplantation including nonadherence to immunosuppressant medication, graft failure, and all-cau

181 f transplant survival using current costs of immunosuppressant medications in the era of generic equi

182 The introduction of generic immunosuppressant medications may present an opportunity

183 e most commonly prescribed anti-inflammatory/immunosuppressant medications worldwide.

184 days in the absence of any corticosteroid or immunosuppressant medications.

185 food allergen avoidance, and use of systemic immunosuppressant medications.

186 medications are associated with adherence to immunosuppressant medications.

187 kedly between centers (range, 0%-58%) and by immunosuppressant medications.

188 or multiple sclerosis, previous therapy with immunosuppressants might increase risk.

189 Furthermore, administration of the immunosuppressant minocycline or an inhibitor of IL-1bet

190 ry, rats of both lines were treated with the immunosuppressant mycophenolate mofetil (MMF).

191 Clinical studies suggest that the immunosuppressant mycophenolate mofetil is associated wi

192 Immunosuppressant mycophenolate mofetil treatment of enr

193 novel nanogel drug delivery vehicle for the immunosuppressant mycophenolic acid (MPA).

194 ntation (n=4) or were treated with long-term immunosuppressants (n=3).

195 actice of anti-JCV antibody index testing of immunosuppressant-naive patients with MS, either current

196 investigated the effect of morphine, a known immunosuppressant, on leukocyte migration and recruitmen

197 ontrol group with trough-level monitoring of immunosuppressants or to an intervention group with addi

198 CD and inadequate response or intolerance to immunosuppressants or tumor necrosis factor antagonists.

199 tion of penicillins (OR, 6.12; P = .03), and immunosuppressants (OR, 7.00; P = .002); (2) day 7, base

200 olved either by holding the drug, initiating immunosuppressants, or both, and rates of recurrent toxi

201 agectomy with neoadjuvant therapy is also in immunosuppressant patients feasible without increased ri

202 hen confirm genetic variants associated with immunosuppressant pharmacokinetics and adverse outcomes.

203 Azathioprine, a purine antimetabolite immunosuppressant, photosensitizes the skin and causes t

204 lmodulin-regulated phosphatase and target of immunosuppressants, plays important roles in the circula

205 duscin is one such isocyanide-functionalized immunosuppressant produced in Xenorhabdus and Photorhabd

206 The immunosuppressant rapamycin (RAPA) inhibits mTORC1 but n

207 rated via FNP that were dual loaded with the immunosuppressant rapamycin and a fluorescent dye to lin

208 The immunosuppressant rapamycin frequently causes noninfecti

209 to derive a binding site hotspot map for the immunosuppressant rapamycin, a complex macrocyclic natur

210 s increased, pharmacokinetic (PK) studies of immunosuppressants rarely include older patients.

211 meters were gender, age, transplanted organ, immunosuppressant regimen, time between transplantation

212 replication under therapy and the impact of immunosuppressant regimens on viral replication are unkn

213 is lost through multiple factors, including immunosuppressant-related toxicity, often requiring more

214 ween myositis (and other immune-mediated and immunosuppressant-responsive disorders) and its many cli

215 suppressants (RR = 5.6, PPV23 = 68%), and no immunosuppressants (RR = 1 [reference], PPV23 = 74%).

216 rticosteroids (RR = 6.2, PPV23 = 64%), other immunosuppressants (RR = 5.6, PPV23 = 68%), and no immun

217 ydroxyphenylalanyl-(3S)-piperazate common to immunosuppressant sanglifehrins was synthesized from the

218 t factors with which to guide individualized immunosuppressant selections over time.

219 also loaded with cyclophosphamide (CYC), an immunosuppressant shown to reduce the cerebrovascular in

220 Although regarded primarily as an immunosuppressant signal, cAMP has been found to mediate

221 BMI, race, diabetes, COPD, OR time>2 hours, immunosuppressants, smoking, active infection, ASA class

222 immunoglobulin or plasmapheresis before oral immunosuppressants start having an effect.

223 s, 96 patients) and find that antivirals and immunosuppressants strongly affect the structure of the

224 There was no correlation between immunosuppressant studied drugs and any of the studied v

225 amethasone is a potent anti-inflammatory and immunosuppressant substance.

226 e, including antibiotics such as penicillin, immunosuppressants such as cyclosporine, and cytostatics

227 suppress in allograft recipients exposed to immunosuppressants, such as tacrolimus (TAC).

228 approval of narrow therapeutic index generic immunosuppressants, such as tacrolimus, in transplant re

229 ytotoxicity of the calcineurin inhibitor and immunosuppressant tacrolimus (FK-506) was prevented by N

230 sensory neurons as molecular targets of the immunosuppressant tacrolimus.

231 The immunosuppressants tacrolimus and mycophenolate are impo

232 The effect of an immunosuppressant, Tacrolimus, is also confirmed in the

233 In conclusion, this study discovers that immunosuppressant TAM kinases are promoters of pro-infla

234 e occurred in 16 (55%) of 29 patients during immunosuppressant taper or discontinuation.

235 ponse was detected in vitro and conventional immunosuppressants targeting T cell activation had limit

236 ycophenolic acid (MPA) is a highly effective immunosuppressant that has broad antiviral activity agai

237 Cyclosporine (CsA) is an immunosuppressant that is highly effective for severe di

238 2CA acts as narrow-spectrum immunosuppressant that selectively targets lymphocyte po

239 1/3 inhibitor R507 is a very well-tolerated immunosuppressant that similarly diminished obliterative

240 urrently treated using mainly broad-spectrum immunosuppressants that can lead to adverse side effects

241 res treatment with nonspecific pharmacologic immunosuppressants that carry both systemic and nephrolo

242 nses can be limited with the use of systemic immunosuppressants, the induction of regulatory cell pop

243 6 may represent an optimal target for future immunosuppressant therapeutics with a particular role in

244 Immunosuppressant therapies should be considered in this

245 n the conventional management group required immunosuppressant therapy (61%; median time to first pre

246 ), only 1/14 patients achieved response with immunosuppressant therapy alone.

247 ing for CRMP5 IgG to expedite vision-sparing immunosuppressant therapy and a targeted search for a sy

248 ents achieved response with a combination of immunosuppressant therapy and thrombopoietin-receptor ag

249 Early aggressive immunosuppressant therapy improved outcomes, and risk of

250 Patients often must choose between long-term immunosuppressant therapy or total colectomy.

251 Immunosuppressant therapy reduced the relapse rate in bo

252 Combining an immunosuppressant therapy with thrombopoietin-receptor a

253 d infectious contexts, and/or anti-rejection immunosuppressant therapy.

254 tica spectrum disorder (NMOSD) when added to immunosuppressant therapy.

255 ent cohort included 76 patients who received immunosuppressant therapy; the remaining 82 patients did

256 ects of standard treatment (glucocorticoids, immunosuppressants), there is an unmet need for safe and

257 erlying illnesses and the use of concomitant immunosuppressants; therefore, a clear causal relationsh

258 ought to establish the ability of a systemic immunosuppressant to modulate immune and epidermal alter

259 ence supports therapeutic monitoring of this immunosuppressant to optimize its efficacy and reduce to

260 The addition of transplant immunosuppressants to an already immunocompromised state

261 oactive compounds, ranging from statins over immunosuppressants to antibiotics.

262 ential for the immune response and target of immunosuppressants, to the PxIxIT SLiM.

263 When combined with immunosuppressant toxicity, post-transplant diabetes and

264 eated with corticosteroids (83%), 11 with an immunosuppressant treatment (27%) and 5 with biological

265 ntibodies are being identified and receiving immunosuppressant treatment earlier and more aggressivel

266 Patients were divided into 2 subgroups: an immunosuppressant treatment group and a nonimmunosuppres

267 story of hepatic encephalopathy (P = 0.033), immunosuppressant treatment protocol (P = 0.041), donor

268 nd understand the putative new bile acid and immunosuppressant treatment strategies under development

269 Randomisation was stratified by baseline immunosuppressant treatment.

270 In patients without previous immunosuppressant use (n=18 616), estimated annual PML r

271 % (95% CI 1.8-4.0) in patients with previous immunosuppressant use and 1.7% (1.4-2.1) in those withou

272 Neither natalizumab exposure nor prior immunosuppressant use appear to affect prevalence.

273 cumulative PML risk with or without previous immunosuppressant use was estimated using Kaplan-Meier a

274 am virus (JCV) antibodies in serum, previous immunosuppressant use, and treatment duration, which wer

275 In patients with no prior immunosuppressant use, anti-JCV antibody index distribut

276 gy for cephalosporins, known kidney disease, immunosuppressant use, or pregnancy.

277 regardless of natalizumab exposure or prior immunosuppressant use, p = 0.9709 and p = 0.6632, respec

278 antibody-positive patients without previous immunosuppressant use, risk estimates were further strat

279 antibody-positive MS patients with no prior immunosuppressant use.

280 ues of anti-JCV antibody status and previous immunosuppressant use.

281 rin inhibitor (CNI) cyclosporine A (CsA), an immunosuppressant used to prevent allograft rejection, c

282 ine and tacrolimus are calcineurin inhibitor immunosuppressants used to prevent organ rejection after

283 FICANCE STATEMENT Calcineurin inhibitors are immunosuppressants used to prevent rejection of transpla

284 n equation approach revealed that the use of immunosuppressants was an independent predictor for slow

285 ystemic corticosteroids, antihistamines, and immunosuppressants was unsuccessful.

286 In an effort to discover novel immunosuppressants we used cytokine ELISPOT and ELISAs t

287 Calcineurin inhibitor-based immunosuppressants were given.

288 filtration rates, and concentrations of the immunosuppressants were measured along with (1)H-magneti

289 The associated immunosuppressants were tapered after administering 3 ad

290 er drugs (eg, penicillins, fluoroquinolones, immunosuppressants) were the strongest predictors of ren

291 Although morphine is a known immunosuppressant, whether it directly induces virulence

292 alcineurin inhibitors (CNIs) are 2 effective immunosuppressants which are essential to prevent allogr

293 ELPs) fused with FKBP12, to deliver a potent immunosuppressant with dose-limiting toxicity, rapamycin

294 onist effect of tacrolimus, a potent natural immunosuppressant with multiple clinical applications, o

295 al target of tacrolimus (FK506), a macrolide immunosuppressant with several clinical uses, including

296 thermore, immunosuppression therapy based on immunosuppressants with antitumoral effects should be pr

297 Both R507 and R545 are potent novel immunosuppressants with favorable pharmacokinetics and h

298 Allograft survival despite complete immunosuppressant withdrawal has been demonstrated in se

299 erogenic therapies, and to allow intelligent immunosuppressant withdrawal in patients whose autoimmun

300 Immunosuppressant withdrawal resulted in CDC positivity